Bicara Therapeutics
BCAX
84 hedge funds and large institutions have $814M invested in Bicara Therapeutics in 2024 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 24 closing their positions.
229% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 7
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
63% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 24
22% more funds holding
Funds holding: 69 → 84 (+15)
18.87% more ownership
Funds ownership: 66.96% → 85.83% (+19%)
12% less capital invested
Capital invested by funds: $928M → $814M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$28.6M |
| 2 |
BlackRock
New York
|
+$26.3M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$25M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.2M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$20.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.47M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$6.75M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.96M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$5.09M |
BCAX Hedge Fund Activity: Q4 2024 in Review
84 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q4 2024, worth a combined $814M — down 12% from $928M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new BCAX positions and 24 closed out — a net gain of 15 holders — while 23 added to existing stakes and 7 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $28.6M. The largest seller was Logos Global Management, exiting entirely with an estimated $20.4M sold.
- 84 institutional investors held Bicara Therapeutics (BCAX) as of Q4 2024, up from 69 in Q3 2024.
- Funds reported $814M of Bicara Therapeutics stock for Q4 2024, down 12% quarter-over-quarter.
- 39 funds opened new Bicara Therapeutics positions in Q4 2024 and 24 closed out, a net change of +15 holders.
- The largest Bicara Therapeutics buyer in Q4 2024 was Adage Capital Partners, an estimated $28.6M added.
- The largest Bicara Therapeutics seller in Q4 2024 was Logos Global Management, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2024.